Velaglucerase beta not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “All subjects will receive velaglucerase beta 60 U/kg IV Q2W for 37 weeks with two weeks of follow-up through Week 39 (9 months).”In the company’s words, NCT07847411 on ClinicalTrials.gov
- Main trialPhase 3
- “This is a Phase 3, multicenter, open-label, single-arm study to evaluate the safety, efficacy, PK, PD, and immunogenicity of velaglucerase beta in untreated children with GD1 or GD3 for 39 weeks.”In the company’s words, NCT07847411 on ClinicalTrials.gov
Other drugs for Gaucher Disease
- NizubaglustatAzafaros B.V. · Phase 2/3
- GZ/SAR402671Sanofi · Phase 3
- ImigluceraseSanofi · Phase 3
- LY3884961Prevail Therapeutics · Phase 1/2
- VGN-R08bShanghai Vitalgen BioPharma Co., Ltd. · Phase 1/2
- YH35995Yuhan Corporation · Phase 1
Coming up1
- 25 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 25 Feb 2028 | Study of Velaglucerase Beta ERT in Children With Gaucher Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026